Vanda Pharmaceuticals Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on February 19, 2020, reporting events that occurred on February 14, 2020. The filing addresses changes to the Company's Board of Directors, specifically the resignation of a director and the appointment of a new director to fill the vacancy.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Michael F. Cola resigned from the Board of Directors and all committees effective immediately on February 14, 2020, to devote full-time efforts to other commitments. He had served since 2012.
- Appointment: Stephen Ray Mitchell, M.D., M.B.A., was appointed as a director effective immediately following Mr. Cola's resignation. His initial term expires at the 2022 annual meeting of stockholders.
- Committee Changes: Anne Sempowski Ward was appointed to the Audit Committee, and H. Thomas Watkins was appointed Chair of the Nominating/Corporate Governance Committee to replace Mr. Cola.
Compensation and Governance Details
Dr. Mitchell's compensation package includes:
- Annual Fee: $45,000, payable quarterly.
- Initial Stock Option: 35,000 shares at an exercise price of $12.70 per share (closing price on Feb 14, 2020). Vesting is 25% after one year, with the remaining 75% vesting monthly over three years.
- Annual Awards: Eligible for an option to purchase 10,000 shares and 5,000 restricted stock units upon the conclusion of each annual meeting starting in 2020. These vest one year from the grant date.
- Change of Control: All equity awards accelerate to 100% vesting in the event of a change of control.
- Independence: The Board determined Dr. Mitchell is an independent director.
Key Facts for Investor Verification
- Verify the impact of the Board composition change on the Company's strategic direction and oversight.
- Review the full text of the press release (Exhibit 99.1) for additional context on Dr. Mitchell's background.
- Monitor the upcoming 2020 Definitive Proxy Statement for detailed disclosure of the outside director compensation program.
- Confirm the vesting schedule and exercise price of the new director's equity awards against current market conditions.